세계의 정신과 디지털 바이오마커 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 임상 진료별, 최종 용도별, 지역별, 전망과 예측(2024-2031년)

The Global Psychiatric Digital Biomarkers Market size is expected to reach $2.78 billion by 2031, rising at a market growth of 24.1% CAGR during the forecast period.

Europe's increasing awareness of the importance of real-time monitoring and predictive analytics in mental health further drives the market's growth in the region. Therefore, the Europe segment acquired 23% revenue share in the market in 2023. Favorable regulatory environments and public-private partnerships have supported the adoption of digital biomarkers across the region. Countries like Germany, the UK, and France are key contributors, with their investments in AI-driven healthcare and emphasis on personalized mental health care.

Integrating psychiatric digital biomarkers with artificial intelligence (AI) and machine learning (ML) technologies has amplified their potential. These technologies analyze immense quantities of patient data to predict outcomes and identify patterns, thereby assisting clinicians in the development of more precise diagnoses and the optimization of treatment plans. Thus, the shift toward personalized medicine, powered by psychiatric digital biomarkers, not only empowers clinicians but also fosters patient trust and engagement as individuals receive care that is precisely aligned with their unique mental health needs. Additionally, In the private sector, startups and established firms drive innovation in mental health technology. The surge in investment also supports research and development, particularly in integrating digital biomarkers into clinical trials. Pharmaceutical companies like Novartis and Pfizer are collaborating with tech firms to utilize wearable and app-based biomarkers for real-time assessment of psychiatric drug efficacy. Therefore, these factors will drive the growth of the market.

However, the reliance on cutting-edge technologies like artificial intelligence (AI), machine learning, and mobile devices in psychiatric digital biomarkers creates significant accessibility challenges. While these technologies can potentially revolutionize mental health care, they also unintentionally exclude populations with limited technological access or low digital literacy. Rural or economically disadvantaged areas, for example, often lack the infrastructure to support these advanced tools, such as reliable internet connectivity or modern smartphones. Hence, these factors may hamper the growth of the market.

Type Outlook

Based on type, the market is classified into wearable, mobile based applications, sensors, and others. The wearable segment garnered 38% revenue share in the market in 2023. The wearable segment is propelled by its capacity to continuously monitor physiological and behavioral parameters, including physical activity, sleep patterns, and pulse rate, which are critical for the evaluation of mental health conditions. The convenience and integration of wearable devices with sophisticated analytics platforms, such as fitness trackers and smartwatches, have made them a popular choice among patients and healthcare providers.

Clinical Practice Outlook

On the basis of clinical practice, the market is divided into diagnostic psychiatric digital biomarkers, monitoring psychiatric digital biomarkers, predictive & prognostic psychiatric digital biomarkers, and others. The monitoring psychiatric digital biomarkers segment recorded 27% revenue share in the market in 2023. The growing emphasis on continuous mental health management and personalized care propels this segment. These biomarkers enable real-time tracking of a patient's mental state, providing valuable data for assessing treatment efficacy and disease progression. The accessibility of monitoring solutions has been expanded by the rising usage of telehealth services and the integration of mobile applications.

End Use Outlook

By end use, the market is segmented into healthcare companies, healthcare providers, payers, and others. The healthcare companies segment witnessed 48% revenue share in the market in 2023. These companies make substantial investments in research and development, utilizing sophisticated technologies such as AI, machine learning, and big data analytics to develop state-of-the-art mental health diagnostics and management solutions. Strategic partnerships with technology firms, academic institutions, and healthcare providers further enhance their ability to develop robust, scalable, and clinically validated products.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment procured 53% revenue share in the market in 2023. The region's high adoption of innovative tools like wearables and mobile applications is bolstered by increasing awareness of mental health issues and strong policy support. Government initiatives promoting digital health, alongside robust funding for mental health research, have further accelerated the growth of psychiatric digital biomarkers in North America. The region's capacity to dominate the market is also improved by the integration of AI and machine learning into healthcare systems.

List of Key Companies Profiled

• Canary Speech, Inc
• Sonde Health, Inc. (Puretech Health Plc)
• Koneksa Health Inc.
• Empatica Inc.
• VivoSense, Inc.
• IXICO Plc
• Neurotrack Technologies, Inc.
• Winterlight Labs
• Aural Analytics, Inc. (Linus Health)

Global Psychiatric Digital Biomarkers Market Report Segmentation

By Type

• Wearable
• Mobile based Applications
• Sensors
• Other Type

By Clinical Practice

• Diagnostic Psychiatric Digital Biomarkers
• Monitoring Psychiatric Digital Biomarkers
• Predictive and Prognostic Psychiatric Digital Biomarkers
• Other Clinical Practice

By End Use

• Healthcare Companies
• Healthcare Providers
• Payers
• Other End Use

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Psychiatric Digital Biomarkers Market, by Type
  • 1.4.2 Global Psychiatric Digital Biomarkers Market, by Clinical Practice
  • 1.4.3 Global Psychiatric Digital Biomarkers Market, by End Use
  • 1.4.4 Global Psychiatric Digital Biomarkers Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
  • 3.2.3 Market Opportunities
  • 3.2.4 Market Challenges
• 3.3 Porter Five Forces Analysis

Chapter 4. Global Psychiatric Digital Biomarkers Market by Type

• 4.1 Global Wearable Market by Region
• 4.2 Global Mobile based Applications Market by Region
• 4.3 Global Sensors Market by Region
• 4.4 Global Other Type Market by Region

Chapter 5. Global Psychiatric Digital Biomarkers Market by Clinical Practice

• 5.1 Global Diagnostic Psychiatric Digital Biomarkers Market by Region
• 5.2 Global Monitoring Psychiatric Digital Biomarkers Market by Region
• 5.3 Global Predictive and Prognostic Psychiatric Digital Biomarkers Market by Region
• 5.4 Global Other Clinical Practice Market by Region

Chapter 6. Global Psychiatric Digital Biomarkers Market by End Use

• 6.1 Global Healthcare Companies Market by Region
• 6.2 Global Healthcare Providers Market by Region
• 6.3 Global Payers Market by Region
• 6.4 Global Other End Use Market by Region

Chapter 7. Global Psychiatric Digital Biomarkers Market by Region

• 7.1 North America Psychiatric Digital Biomarkers Market
  • 7.1.1 North America Psychiatric Digital Biomarkers Market by Type
    • 7.1.1.1 North America Wearable Market by Country
    • 7.1.1.2 North America Mobile based Applications Market by Country
    • 7.1.1.3 North America Sensors Market by Country
    • 7.1.1.4 North America Other Type Market by Country
  • 7.1.2 North America Psychiatric Digital Biomarkers Market by Clinical Practice
    • 7.1.2.1 North America Diagnostic Psychiatric Digital Biomarkers Market by Country
    • 7.1.2.2 North America Monitoring Psychiatric Digital Biomarkers Market by Country
    • 7.1.2.3 North America Predictive and Prognostic Psychiatric Digital Biomarkers Market by Country
    • 7.1.2.4 North America Other Clinical Practice Market by Country
  • 7.1.3 North America Psychiatric Digital Biomarkers Market by End Use
    • 7.1.3.1 North America Healthcare Companies Market by Country
    • 7.1.3.2 North America Healthcare Providers Market by Country
    • 7.1.3.3 North America Payers Market by Country
    • 7.1.3.4 North America Other End Use Market by Country
  • 7.1.4 North America Psychiatric Digital Biomarkers Market by Country
    • 7.1.4.1 US Psychiatric Digital Biomarkers Market
      • 7.1.4.1.1 US Psychiatric Digital Biomarkers Market by Type
      • 7.1.4.1.2 US Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.1.4.1.3 US Psychiatric Digital Biomarkers Market by End Use
    • 7.1.4.2 Canada Psychiatric Digital Biomarkers Market
      • 7.1.4.2.1 Canada Psychiatric Digital Biomarkers Market by Type
      • 7.1.4.2.2 Canada Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.1.4.2.3 Canada Psychiatric Digital Biomarkers Market by End Use
    • 7.1.4.3 Mexico Psychiatric Digital Biomarkers Market
      • 7.1.4.3.1 Mexico Psychiatric Digital Biomarkers Market by Type
      • 7.1.4.3.2 Mexico Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.1.4.3.3 Mexico Psychiatric Digital Biomarkers Market by End Use
    • 7.1.4.4 Rest of North America Psychiatric Digital Biomarkers Market
      • 7.1.4.4.1 Rest of North America Psychiatric Digital Biomarkers Market by Type
      • 7.1.4.4.2 Rest of North America Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.1.4.4.3 Rest of North America Psychiatric Digital Biomarkers Market by End Use
• 7.2 Europe Psychiatric Digital Biomarkers Market
  • 7.2.1 Europe Psychiatric Digital Biomarkers Market by Type
    • 7.2.1.1 Europe Wearable Market by Country
    • 7.2.1.2 Europe Mobile based Applications Market by Country
    • 7.2.1.3 Europe Sensors Market by Country
    • 7.2.1.4 Europe Other Type Market by Country
  • 7.2.2 Europe Psychiatric Digital Biomarkers Market by Clinical Practice
    • 7.2.2.1 Europe Diagnostic Psychiatric Digital Biomarkers Market by Country
    • 7.2.2.2 Europe Monitoring Psychiatric Digital Biomarkers Market by Country
    • 7.2.2.3 Europe Predictive and Prognostic Psychiatric Digital Biomarkers Market by Country
    • 7.2.2.4 Europe Other Clinical Practice Market by Country
  • 7.2.3 Europe Psychiatric Digital Biomarkers Market by End Use
    • 7.2.3.1 Europe Healthcare Companies Market by Country
    • 7.2.3.2 Europe Healthcare Providers Market by Country
    • 7.2.3.3 Europe Payers Market by Country
    • 7.2.3.4 Europe Other End Use Market by Country
  • 7.2.4 Europe Psychiatric Digital Biomarkers Market by Country
    • 7.2.4.1 Germany Psychiatric Digital Biomarkers Market
      • 7.2.4.1.1 Germany Psychiatric Digital Biomarkers Market by Type
      • 7.2.4.1.2 Germany Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.2.4.1.3 Germany Psychiatric Digital Biomarkers Market by End Use
    • 7.2.4.2 UK Psychiatric Digital Biomarkers Market
      • 7.2.4.2.1 UK Psychiatric Digital Biomarkers Market by Type
      • 7.2.4.2.2 UK Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.2.4.2.3 UK Psychiatric Digital Biomarkers Market by End Use
    • 7.2.4.3 France Psychiatric Digital Biomarkers Market
      • 7.2.4.3.1 France Psychiatric Digital Biomarkers Market by Type
      • 7.2.4.3.2 France Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.2.4.3.3 France Psychiatric Digital Biomarkers Market by End Use
    • 7.2.4.4 Russia Psychiatric Digital Biomarkers Market
      • 7.2.4.4.1 Russia Psychiatric Digital Biomarkers Market by Type
      • 7.2.4.4.2 Russia Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.2.4.4.3 Russia Psychiatric Digital Biomarkers Market by End Use
    • 7.2.4.5 Spain Psychiatric Digital Biomarkers Market
      • 7.2.4.5.1 Spain Psychiatric Digital Biomarkers Market by Type
      • 7.2.4.5.2 Spain Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.2.4.5.3 Spain Psychiatric Digital Biomarkers Market by End Use
    • 7.2.4.6 Italy Psychiatric Digital Biomarkers Market
      • 7.2.4.6.1 Italy Psychiatric Digital Biomarkers Market by Type
      • 7.2.4.6.2 Italy Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.2.4.6.3 Italy Psychiatric Digital Biomarkers Market by End Use
    • 7.2.4.7 Rest of Europe Psychiatric Digital Biomarkers Market
      • 7.2.4.7.1 Rest of Europe Psychiatric Digital Biomarkers Market by Type
      • 7.2.4.7.2 Rest of Europe Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.2.4.7.3 Rest of Europe Psychiatric Digital Biomarkers Market by End Use
• 7.3 Asia Pacific Psychiatric Digital Biomarkers Market
  • 7.3.1 Asia Pacific Psychiatric Digital Biomarkers Market by Type
    • 7.3.1.1 Asia Pacific Wearable Market by Country
    • 7.3.1.2 Asia Pacific Mobile based Applications Market by Country
    • 7.3.1.3 Asia Pacific Sensors Market by Country
    • 7.3.1.4 Asia Pacific Other Type Market by Country
  • 7.3.2 Asia Pacific Psychiatric Digital Biomarkers Market by Clinical Practice
    • 7.3.2.1 Asia Pacific Diagnostic Psychiatric Digital Biomarkers Market by Country
    • 7.3.2.2 Asia Pacific Monitoring Psychiatric Digital Biomarkers Market by Country
    • 7.3.2.3 Asia Pacific Predictive and Prognostic Psychiatric Digital Biomarkers Market by Country
    • 7.3.2.4 Asia Pacific Other Clinical Practice Market by Country
  • 7.3.3 Asia Pacific Psychiatric Digital Biomarkers Market by End Use
    • 7.3.3.1 Asia Pacific Healthcare Companies Market by Country
    • 7.3.3.2 Asia Pacific Healthcare Providers Market by Country
    • 7.3.3.3 Asia Pacific Payers Market by Country
    • 7.3.3.4 Asia Pacific Other End Use Market by Country
  • 7.3.4 Asia Pacific Psychiatric Digital Biomarkers Market by Country
    • 7.3.4.1 China Psychiatric Digital Biomarkers Market
      • 7.3.4.1.1 China Psychiatric Digital Biomarkers Market by Type
      • 7.3.4.1.2 China Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.3.4.1.3 China Psychiatric Digital Biomarkers Market by End Use
    • 7.3.4.2 Japan Psychiatric Digital Biomarkers Market
      • 7.3.4.2.1 Japan Psychiatric Digital Biomarkers Market by Type
      • 7.3.4.2.2 Japan Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.3.4.2.3 Japan Psychiatric Digital Biomarkers Market by End Use
    • 7.3.4.3 India Psychiatric Digital Biomarkers Market
      • 7.3.4.3.1 India Psychiatric Digital Biomarkers Market by Type
      • 7.3.4.3.2 India Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.3.4.3.3 India Psychiatric Digital Biomarkers Market by End Use
    • 7.3.4.4 South Korea Psychiatric Digital Biomarkers Market
      • 7.3.4.4.1 South Korea Psychiatric Digital Biomarkers Market by Type
      • 7.3.4.4.2 South Korea Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.3.4.4.3 South Korea Psychiatric Digital Biomarkers Market by End Use
    • 7.3.4.5 Singapore Psychiatric Digital Biomarkers Market
      • 7.3.4.5.1 Singapore Psychiatric Digital Biomarkers Market by Type
      • 7.3.4.5.2 Singapore Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.3.4.5.3 Singapore Psychiatric Digital Biomarkers Market by End Use
    • 7.3.4.6 Malaysia Psychiatric Digital Biomarkers Market
      • 7.3.4.6.1 Malaysia Psychiatric Digital Biomarkers Market by Type
      • 7.3.4.6.2 Malaysia Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.3.4.6.3 Malaysia Psychiatric Digital Biomarkers Market by End Use
    • 7.3.4.7 Rest of Asia Pacific Psychiatric Digital Biomarkers Market
      • 7.3.4.7.1 Rest of Asia Pacific Psychiatric Digital Biomarkers Market by Type
      • 7.3.4.7.2 Rest of Asia Pacific Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.3.4.7.3 Rest of Asia Pacific Psychiatric Digital Biomarkers Market by End Use
• 7.4 LAMEA Psychiatric Digital Biomarkers Market
  • 7.4.1 LAMEA Psychiatric Digital Biomarkers Market by Type
    • 7.4.1.1 LAMEA Wearable Market by Country
    • 7.4.1.2 LAMEA Mobile based Applications Market by Country
    • 7.4.1.3 LAMEA Sensors Market by Country
    • 7.4.1.4 LAMEA Other Type Market by Country
  • 7.4.2 LAMEA Psychiatric Digital Biomarkers Market by Clinical Practice
    • 7.4.2.1 LAMEA Diagnostic Psychiatric Digital Biomarkers Market by Country
    • 7.4.2.2 LAMEA Monitoring Psychiatric Digital Biomarkers Market by Country
    • 7.4.2.3 LAMEA Predictive and Prognostic Psychiatric Digital Biomarkers Market by Country
    • 7.4.2.4 LAMEA Other Clinical Practice Market by Country
  • 7.4.3 LAMEA Psychiatric Digital Biomarkers Market by End Use
    • 7.4.3.1 LAMEA Healthcare Companies Market by Country
    • 7.4.3.2 LAMEA Healthcare Providers Market by Country
    • 7.4.3.3 LAMEA Payers Market by Country
    • 7.4.3.4 LAMEA Other End Use Market by Country
  • 7.4.4 LAMEA Psychiatric Digital Biomarkers Market by Country
    • 7.4.4.1 Brazil Psychiatric Digital Biomarkers Market
      • 7.4.4.1.1 Brazil Psychiatric Digital Biomarkers Market by Type
      • 7.4.4.1.2 Brazil Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.4.4.1.3 Brazil Psychiatric Digital Biomarkers Market by End Use
    • 7.4.4.2 Argentina Psychiatric Digital Biomarkers Market
      • 7.4.4.2.1 Argentina Psychiatric Digital Biomarkers Market by Type
      • 7.4.4.2.2 Argentina Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.4.4.2.3 Argentina Psychiatric Digital Biomarkers Market by End Use
    • 7.4.4.3 UAE Psychiatric Digital Biomarkers Market
      • 7.4.4.3.1 UAE Psychiatric Digital Biomarkers Market by Type
      • 7.4.4.3.2 UAE Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.4.4.3.3 UAE Psychiatric Digital Biomarkers Market by End Use
    • 7.4.4.4 Saudi Arabia Psychiatric Digital Biomarkers Market
      • 7.4.4.4.1 Saudi Arabia Psychiatric Digital Biomarkers Market by Type
      • 7.4.4.4.2 Saudi Arabia Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.4.4.4.3 Saudi Arabia Psychiatric Digital Biomarkers Market by End Use
    • 7.4.4.5 South Africa Psychiatric Digital Biomarkers Market
      • 7.4.4.5.1 South Africa Psychiatric Digital Biomarkers Market by Type
      • 7.4.4.5.2 South Africa Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.4.4.5.3 South Africa Psychiatric Digital Biomarkers Market by End Use
    • 7.4.4.6 Nigeria Psychiatric Digital Biomarkers Market
      • 7.4.4.6.1 Nigeria Psychiatric Digital Biomarkers Market by Type
      • 7.4.4.6.2 Nigeria Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.4.4.6.3 Nigeria Psychiatric Digital Biomarkers Market by End Use
    • 7.4.4.7 Rest of LAMEA Psychiatric Digital Biomarkers Market
      • 7.4.4.7.1 Rest of LAMEA Psychiatric Digital Biomarkers Market by Type
      • 7.4.4.7.2 Rest of LAMEA Psychiatric Digital Biomarkers Market by Clinical Practice
      • 7.4.4.7.3 Rest of LAMEA Psychiatric Digital Biomarkers Market by End Use

Chapter 8. Company Profiles

• 8.1 Canary Speech, Inc.
  • 8.1.1 Company Overview
  • 8.1.2 SWOT Analysis
• 8.2 Sonde Health, Inc. (Puretech Health Plc)
  • 8.2.1 Company Overview
  • 8.2.2 Financial Analysis
  • 8.2.3 Research & Development Expenses
  • 8.2.4 Recent strategies and developments:
    • 8.2.4.1 Partnerships, Collaborations, and Agreements:
    • 8.2.4.2 Product Launches and Product Expansions:
  • 8.2.5 SWOT Analysis
• 8.3 Koneksa Health Inc.
  • 8.3.1 Company Overview
• 8.4 Empatica Inc.
  • 8.4.1 Company Overview
• 8.5 VivoSense, Inc.
  • 8.5.1 Company Overview
• 8.6 IXICO plc
  • 8.6.1 Company Overview
• 8.7 Neurotrack Technologies, Inc.
  • 8.7.1 Company Overview
• 8.8 WinterLight Labs
  • 8.8.1 Company Overview
• 8.9 Aural Analytics, Inc. (Linus Health)
  • 8.9.1 Company Overview

Chapter 9. Winning Imperatives of Psychiatric Digital Biomarkers Market